Podcast

October 20, 2019

Podcast: This Week in Managed Care—New Long-term Opioid Use Guidelines and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care^® recaps the top managed care news of the week.

This week, the top managed care news included a new guide that balances curbs on opioid abuse with the needs of patients with chronic pain; HHS proposed reforming antikickback rules to help boost value-based care; a report found flaws with Medicaid work requirements.

Listen above or through one of these podcast services:

HHS Issues Guide to Reducing Long-term Opioid Use Without Harming Patients in Chronic Pain

HHS Releases Proposal to Reform Stark Law, Antikickback Rules

What We're Reading: EPA Revises Lead and Copper Rule; Monitoring Vaping-Related Illnesses; GAO Study Faults CMS

What We're Reading: Gottlieb Calls for THC Vape Ban; Tackling Drug Shortages; Air Pollution and Miscarriages

Patient-Centered Oncology Care^®

Evidence-Based Oncology™—October 2019

Read more about the stories in this podcast:

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Andrew Kuykendall, MD, Moffitt Cancer Center

Dr Sundar Jagannath

4 experts in this video

4 experts in this video

Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS

World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com

Dr Sundar Jagannath

1 expert in this video

4 experts in this video

Related Content

The authors reported robust correlations between composite mean greyscale values and key functional outcomes in DMD. | Image Credit: hafakot - stock.adobe.com

July 29th 2025

Quantitative Muscle Ultrasound a Promising Noninvasive Biomarker for DMD

Kimberly Rath, PharmD

Quantitative muscle ultrasound correlates strongly with ambulatory and timed function tests in Duchenne muscular dystrophy, suggesting it could complement or even replace more burdensome assessments.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com

July 29th 2025

Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

AJMC Contributor

A recent study suggests hemorrhagic events following essential thrombocythemia diagnosis are among the most significant predictors of early death.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

Related Content

The authors reported robust correlations between composite mean greyscale values and key functional outcomes in DMD. | Image Credit: hafakot - stock.adobe.com

July 29th 2025

Quantitative Muscle Ultrasound a Promising Noninvasive Biomarker for DMD

Kimberly Rath, PharmD

Quantitative muscle ultrasound correlates strongly with ambulatory and timed function tests in Duchenne muscular dystrophy, suggesting it could complement or even replace more burdensome assessments.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com

July 29th 2025

Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

AJMC Contributor

A recent study suggests hemorrhagic events following essential thrombocythemia diagnosis are among the most significant predictors of early death.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

July 29th 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions